Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development
22. Januar 2025 09:00 ET
|
BIOXYTRAN, INC.
- Repurchasing all convertible note overhang, and - Funding pre-clinical and clinical trials - Management forfeiting $460,000 in accrued payroll BOSTON, MASSACHUSETTS, Jan. 22, 2025 (GLOBE...
Serina Therapeutics Announces Sale of UniverXome Subsidiary
15. Januar 2025 16:05 ET
|
Serina Therapeutics, Inc.
- Transaction eliminates $11.2 million in debt, strengthening financial position - HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics Inc. (“Serina”) (NYSE American: SER), a...
Bioxytran Announces Government Interest After Initial BARDA Techwatch Light Meeting
07. Januar 2025 09:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Jan. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral...
FOXO TECHNOLOGIES INC. ANOUNCES DETAILS OF ITS 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 31, 2024
23. Dezember 2024 09:25 ET
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold its 2024 Annual General Meeting of its Shareholders at 9:30 am...
FOXO TECHNOLOGIES INC. ANNOUNCES THAT STOCKHOLDERS EQUITY IS GREATER THAN $4M, WHICH IS REQUIRED TO MEET THE CONTINUED LISTING REQUIREMENTS OF THE NYSE AMERICAN EXCHANGE
16. Dezember 2024 12:32 ET
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”) announces that recent transactions have led to the Company having...
FOXO TECHNOLOGIES INC. ANNOUNCES RESTRUCTURING AND CAPITAL RAISING TRANSACTIONS AND APPOINTS SEAMUS LAGAN AS CHIEF EXECUTIVE OFFICER
11. Dezember 2024 08:00 ET
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Dec. 11, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”) announces a series of restructuring and capital raising transactions which...
GRI Bio to Participate in the Virtual Investor Closing Bell Series
06. Dezember 2024 08:35 ET
|
GRI Bio, Inc.
Live webcast on Thursday, December 12th at 4:00 PM ET LA JOLLA, CA, Dec. 06, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an...
FOXO TECHNOLOGIES INC. ANNOUNCES RESULTS OF SPECIAL MEETING OF SHAREHOLDERS
02. Dezember 2024 08:00 ET
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Dec. 02, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), announces results of its Special Meeting of its Shareholders that was held...
FOXO TECHNOLOGIES INC., CONFIRMS DETAILS OF SPECIAL MEETING OF SHAREHOLDERS ON NOVEMBER 29, 2024.
25. November 2024 11:15 ET
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Nov. 25, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold its previously announced Special Meeting of its Shareholders at...
FOXO TECHNOLOGIES INC., CONFIRMS DETAILS OF SPECIAL MEETING OF SHAREHOLDERS ON DECEMBER 29, 2024.
25. November 2024 08:00 ET
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Nov. 25, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold its previously announced Special Meeting of its Shareholders at...